CRISPR Therapeutics shares steady as Barclays maintains rating

Investing.com - CRISPR Therapeutics (NASDAQ:CRSP) stock remained unchanged as Barclays (LON:BARC) maintained its Equalweight rating and $42.00 price target on Thursday. According to InvestingPro data, the stock has shown strong momentum with a 16% return over the past six months, though technical indicators suggest it may be entering overbought territory.

The research firm reported additional Phase 1 data for CTX310, CRISPR’s in vivo CRISPR/Cas9 treatment targeting ANGPTL3. The updated results showed peak triglyceride reductions of up to 82% and increased peak LDL reductions of up to 86% for a single patient at the highest dose level, with the length of follow-up unspecified.

Safety and tolerability remained consistent with previous updates, with no clinically significant changes in liver enzymes reported. CRISPR Therapeutics plans to present complete Phase 1 data for CTX310 at a medical meeting in the second half of 2025.

The company also announced a delay in its CTX320 program, which targets Lp(a) using CRISPR/Cas9 knockout technology. The Phase 1 dose escalation update for patients with elevated Lp(a) is now expected in the first half of 2026, pushed back from the previously anticipated second quarter of 2025, to incorporate emerging findings from the Lp(a) landscape.

CRISPR’s preclinical CTX340 program, which targets AGT for refractory hypertension, continues to progress through IND/CTA-enabling studies according to the Barclays report.

In other recent news, CRISPR Therapeutics reported promising Phase 1 clinical data for its experimental cholesterol drug CTX310, showing significant reductions in triglycerides and LDL cholesterol levels. The company highlighted peak reductions of up to 82% in triglycerides and 86% in LDL cholesterol, with a well-tolerated safety profile. In addition, CRISPR Therapeutics announced a strategic delay in the CTX320 data release to incorporate emerging insights, now expected in the first half of 2026. Analyst firm William Blair reiterated its outperform rating on CRISPR Therapeutics, citing competitive clinical data for the CTX310 program and potential business development opportunities. Meanwhile, Citizens JMP maintained its Market Outperform rating and $86.00 price target, acknowledging the progress in CRISPR Therapeutics’ in-vivo programs and recent collaboration with Sirius Therapeutics. This partnership aims to develop new siRNA therapies, with the SRSD107 asset expected to enter pivotal trials next year. Furthermore, CRISPR Therapeutics shareholders approved key proposals at the 2025 Annual General Meeting, including amendments to the company’s Articles of Association and the election of board members. The company also reported advancements in its preclinical cardiovascular program CTX340, targeting refractory hypertension.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.